Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

(2020) Brian O’Neil et al.   JOURNAL OF INFECTIOUS DISEASES

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil

(2018) Shinya Omoto et al.   Scientific Reports

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

(2018) Frederick G. Hayden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains

(2018) Woo-Jin Shin et al.   Expert Opinion on Drug Discovery

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

(2018) Robert W Finberg et al.   JOURNAL OF INFECTIOUS DISEASES

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses

(2017) Carel A. van Baalen et al.   VACCINE

JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses

(2016) Yu Fu et al.   ANTIVIRAL RESEARCH

Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit

(2014) Randal A. Byrn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

(2014) Michael P. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Influenza virus resistance to neuraminidase inhibitors

(2013) Mélanie Samson et al.   ANTIVIRAL RESEARCH

Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States

(2009) Nila J. Dharan   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION